• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非转铁蛋白结合铁(NTBI)、不稳定血浆铁(LPI)与铁毒性之间的关系

The Relationship Between Non-Transferrin-Bound Iron (NTBI), Labile Plasma Iron (LPI), and Iron Toxicity.

作者信息

Duca Lorena, Di Pierro Elena, Scaramellini Natalia, Granata Francesca, Graziadei Giovanna

机构信息

SC Medicina ad Indirizzo Metabolico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, Università degli Studi di Milano, 20122 Milan, Italy.

出版信息

Int J Mol Sci. 2025 Jul 3;26(13):6433. doi: 10.3390/ijms26136433.

DOI:10.3390/ijms26136433
PMID:40650208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12249652/
Abstract

Plasma non-transferrin-bound iron (NTBI) comprises multiple subspecies, classified by their composition, chemical reactivity, and susceptibility to chelation. The redox-active and chelatable fraction of NTBI is referred to as labile plasma iron (LPI). The pathophysiological significance of NTBI and LPI lies in their ability to enter cells via alternative transport pathways that are not regulated by the transferrin receptor system or by cellular iron levels. Several mechanisms have been proposed for their cellular entry, including the hijacking of divalent metal transporters and passive diffusion. This unregulated uptake can lead to iron accumulation in vulnerable tissues such as the liver and the heart. NTBI and LPI bypassing normal cellular control mechanisms can rapidly exceed the cell's capacity to safely store excess iron, leading to toxicity. Both NTBI and LPI contribute to oxidative stress by participating in free-radical-generating reactions. However, LPI concentration in the bloodstream may be differentially affected by the mode and extent of iron overload, the presence of residual serum iron-binding activity, and the antioxidant capacity of individual sera. In summary, both NTBI and LPI contribute to iron-mediated toxicity but differ in terms of reactivity, availability, and pathogenic potential depending on the pathophysiological conditions that influence the degree of toxicity.

摘要

血浆非转铁蛋白结合铁(NTBI)由多个亚类组成,根据其组成、化学反应性和对螯合作用的敏感性进行分类。NTBI的氧化还原活性和可螯合部分被称为不稳定血浆铁(LPI)。NTBI和LPI的病理生理意义在于它们能够通过不受转铁蛋白受体系统或细胞铁水平调节的替代转运途径进入细胞。关于它们进入细胞的机制,已经提出了几种,包括劫持二价金属转运体和被动扩散。这种不受调节的摄取会导致铁在肝脏和心脏等易损组织中积累。NTBI和LPI绕过正常的细胞控制机制,会迅速超过细胞安全储存过量铁的能力,从而导致毒性。NTBI和LPI都通过参与产生自由基的反应而导致氧化应激。然而,血液中LPI的浓度可能会受到铁过载的方式和程度、残余血清铁结合活性的存在以及个体血清抗氧化能力的不同影响。总之,NTBI和LPI都导致铁介导的毒性,但根据影响毒性程度的病理生理条件,它们在反应性、可用性和致病潜力方面存在差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/780d/12249652/51402608298f/ijms-26-06433-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/780d/12249652/7c0a7abb20f8/ijms-26-06433-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/780d/12249652/38c10f03d187/ijms-26-06433-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/780d/12249652/51402608298f/ijms-26-06433-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/780d/12249652/7c0a7abb20f8/ijms-26-06433-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/780d/12249652/38c10f03d187/ijms-26-06433-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/780d/12249652/51402608298f/ijms-26-06433-g003.jpg

相似文献

1
The Relationship Between Non-Transferrin-Bound Iron (NTBI), Labile Plasma Iron (LPI), and Iron Toxicity.非转铁蛋白结合铁(NTBI)、不稳定血浆铁(LPI)与铁毒性之间的关系
Int J Mol Sci. 2025 Jul 3;26(13):6433. doi: 10.3390/ijms26136433.
2
Short-Term Memory Impairment短期记忆障碍
3
Diagnostics: Markers of Body Iron Status.诊断:机体铁状态标志物。
Adv Exp Med Biol. 2025;1480:387-398. doi: 10.1007/978-3-031-92033-2_25.
4
3D-QSAR based computational screening of potent ligands against L-type calcium channel (LTCC) protein structure for iron overload in β-thalassemia.基于3D-QSAR的针对β地中海贫血铁过载的L型钙通道(LTCC)蛋白质结构的有效配体的计算筛选。
Comput Biol Med. 2025 Aug;194:110551. doi: 10.1016/j.compbiomed.2025.110551. Epub 2025 Jun 11.
5
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
6
Labile plasma iron in iron overload: redox activity and susceptibility to chelation.铁过载中不稳定血浆铁:氧化还原活性及螯合敏感性
Blood. 2003 Oct 1;102(7):2670-7. doi: 10.1182/blood-2003-03-0807. Epub 2003 Jun 12.
7
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.改善镰状细胞病或地中海贫血患者铁螯合疗法依从性的干预措施。
Cochrane Database Syst Rev. 2018 May 8;5(5):CD012349. doi: 10.1002/14651858.CD012349.pub2.
8
The Labile Side of Iron in Health and Disease: A Narrative Review.健康与疾病中铁的不稳定状态:一篇综述
Adv Exp Med Biol. 2025;1480:47-60. doi: 10.1007/978-3-031-92033-2_4.
9
Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.地中海贫血中的非转铁蛋白结合铁:儿童和老年患者中氧化还原活性形式的差异检测。
Am J Hematol. 2012 Jan;87(1):55-61. doi: 10.1002/ajh.22203. Epub 2011 Nov 28.
10
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

本文引用的文献

1
Management of iron overload: lessons from transfusion-dependent hemoglobinopathies.铁过载的管理:依赖输血的血红蛋白病的经验教训
Blood. 2025 Jan 23;145(4):359-371. doi: 10.1182/blood.2023022502.
2
Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway.静脉铁治疗通过一种新途径导致心肌铁含量的快速和持续升高。
Eur Heart J. 2024 Nov 8;45(42):4497-4508. doi: 10.1093/eurheartj/ehae359.
3
Iron as an emerging therapeutic target in critically ill patients.铁作为危重症患者的一个新兴治疗靶点。
Crit Care. 2023 Dec 4;27(1):475. doi: 10.1186/s13054-023-04759-1.
4
Ferric Carboxymaltose in Heart Failure with Iron Deficiency.铁羧基麦芽糖在缺铁性心力衰竭中的应用。
N Engl J Med. 2023 Sep 14;389(11):975-986. doi: 10.1056/NEJMoa2304968. Epub 2023 Aug 26.
5
Iron chelation therapy.铁螯合疗法
Eur J Haematol. 2023 May;110(5):490-497. doi: 10.1111/ejh.13935. Epub 2023 Feb 8.
6
Overall and complication-free survival in a large cohort of patients with β-thalassemia major followed over 50 years.50 多年来对大量重型β地中海贫血患者的总体生存率和无并发症生存率的研究。
Am J Hematol. 2023 Mar;98(3):381-387. doi: 10.1002/ajh.26798. Epub 2023 Jan 1.
7
Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia.低危骨髓增生异常综合征和β-地中海贫血症中的红细胞生成。
Blood Rev. 2023 May;59:101039. doi: 10.1016/j.blre.2022.101039. Epub 2022 Dec 22.
8
The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron-carbohydrate administration.铁过载状态下及静脉注射铁碳水化合物后可检测到的血浆铁种类的临床相关性。
Am J Hematol. 2023 Mar;98(3):533-540. doi: 10.1002/ajh.26819. Epub 2023 Jan 9.
9
Thalassaemia.地中海贫血症。
Lancet. 2022 Jun 18;399(10343):2310-2324. doi: 10.1016/S0140-6736(22)00536-0. Epub 2022 Jun 9.
10
The (Bio)Chemistry of Non-Transferrin-Bound Iron.非转铁蛋白结合铁的(生物)化学。
Molecules. 2022 Mar 9;27(6):1784. doi: 10.3390/molecules27061784.